linjc16/ctgov huggingface dataset:
Hematology and Clinical Picture in Pediatric COVID-19 Infection

Study Overview
=================
Brief Summary
-----------------
This study is to discuss the different clinical presentations, hematological and laboratory abnormalities in pediatric COVID-19 infection.

Detailed Description
-----------------
This retrospective observational study will be conducted at Benha University Hospital, Benha, Egypt; after approval by the local ethical committee of Faculty of Medicine, Benha University, Egypt. We will include in this retrospective study all pediatric patients who were admitted with confirmed COVID-19 infection with age range from birth to 18 years during the period from April 2020 till July 2020. The diagnosis of COVID-19 infection is based on positive SARS-CoV-2 RNA detection in throat swab specimens by PCR. All data including demography information, contact history, previous history, clinical symptoms, clinical examination on admission, and hematology and laboratory information will be obtained from inpatient medical records.

Official Title
-----------------
Pediatric COVID-19 Infection; Do Clinical Features and Hematological Parameters Predict the Need for ICU Admission?

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -inpatient confirmed COVID-19 infection by PCR Exclusion Criteria: patients with records missing hematology and/or laboratory data, patients transfered to other medical facilities with unknown outcomes, patients with age older than 18 years from the study.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hematological findings | hematological indices; TLC, absolute lymphocytic count, absolute neutrophil count platelet count, N/L ratio and CRP in pediatric COVID-19 infection | at time of admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical presentations | proportion of patients with respiratory and GIT symptoms, proportion of patients needs ICU admission relation between severity and hematologic indices | at time of admission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID19, hematology, pediatric
Influence of Sevoflurane and Desflurane on Postoperative Sore Throat

Study Overview
=================
Brief Summary
-----------------
This investigation is planned to compare the incidence and severity of postoperative sore throat according to the use of sevoflurane or desflurane.

Official Title
-----------------
Influence of Sevoflurane and Desflurane on Postoperative Sore Throat

Conditions
-----------------
Hip Arthroplasty

Intervention / Treatment
-----------------
* Drug: Sevoflurane
* Drug: Desflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-III Patients scheduled for general anesthesia with endotracheal intubation Exclusion Criteria: Difficult airway Friable teeth Rapid sequence induction Recent sore throat Recent upper respiratory infection Asthma Chronic obstructive pulmonary disease Chronic cough Arrhythmia Coronary disease Heart failure Pregnancy Allergy to sevoflurane Allergy to desflurane Fever after halogenated anesthetics Jaundice after halogenated anesthetics Malignant hyperthremia Allergy to remifentanil Friable teeth History of head and neck surgery Multiple intubation attempts Regional anesthetic agents Gastric tube Dexamethasone Severe hypovolemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Sevoflurane<br> | Drug: Sevoflurane<br>* Sevoflurane was used as a maintenance anesthetic agent.<br>|
| Experimental: Desflurane<br> | Drug: Desflurane<br>* Desflurane was used as a maintenance anesthetic agent.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with postoperative sore throat |  | At 24 hr | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with postoperative sore throat |  | At 0, 2, 4 and 24 hr | 
| Number of participants with postoperative hoarseness |  | At 0, 2, 4 and 24 hr | 
| Number of participants with postoperative cough |  | At 0, 2, 4 and 24 hr | 
| Number of participants with postoperative nausea |  | At 0, 2, 4 and 24 hr | 
| Number of participants with postoperative vomiting |  | At 0, 2, 4 and 24 hr | 
| Number of participants with additional pain medication |  | At 0, 2, 4 and 24 hr | 
| Visual analogue scale of postoperative pain |  | At 0, 2, 4 and 24 hr | 
| Number of participants with shivering |  | At 0, 2, 4 and 24 hr | 
| Requirements of analgesics |  | At 0, 2, 4 and 24 hr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
remifentanil, pharyngitis, intubation
Cost-Effectiveness of and Long-Term Outcomes Following Acupuncture Treatment for Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to estimate the cost-effectiveness of acupuncture and to determine the long-term outcomes and health care utilization of people with osteoarthritis (OA) of the knee.

Detailed Description
-----------------
Osteoarthritis (OA) makes up a large proportion of the disability and economic costs in the U.S. The knee is the most common site of OA and is a common cause of disability and the leading indication of total knee replacement in the elderly. There are presently no curative therapies for OA. Recently, increased attention has focused on the use of complementary and alternative medicine (CAM) therapies, such as acupuncture, especially for patients who have failed to respond to more standard therapy. Little is known of the long-term health services utilization and outcomes of patients with knee OA. This study will evaluate the cost effectiveness and overall outcomes of acupuncture for OA treatment. Participants in this study will be randomly assigned to receive either acupuncture or placebo. Surveys and questionnaires will be used to assess participants. Data will be collected on the short- and long-term utilization of health services as well as on pain and physical function.

Official Title
-----------------
Cost-Effectiveness of and Long-Term Outcomes Following Acupuncture Treatment for Osteoarthritis of the Knee

Conditions
-----------------
Osteoarthritis, Knee

Intervention / Treatment
-----------------
* Procedure: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of osteoarthritis (OA)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Acupuncture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Plasma Melatonin AND Mortality After Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).

Official Title
-----------------
Early-morning Plasma Melatonin Levels Predict Cardiovascular Mortality After Acute Myocardial Infarction

Conditions
-----------------
Melatonin, Myocardial Infarction

Intervention / Treatment
-----------------
* Diagnostic Test: plasma melatonin levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: consecutive patients of acute AMI come to department of cardiology, 301 hospital (Beijing, China),absent of cardiogenic shock, and survival for at least 24 h after percutaneous coronary intervention treatment. Exclusion Criteria: patients with autoimmune diseases, collagen tissue diseases, drug addiction, radiotherapy, patients receiving immunosuppressive treatment, taking sedatives, antiepileptic drugs, tricyclic antidepressants or any medication known to influence melatonin metabolism, psychiatric sleeping disorders, shift workers, and subjects with jet-lag syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: plasma melatonin levels|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular mortality |  | The median follow-up was 31.6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| non-cardiovascular mortality |  | The median follow-up was 31.6 months | 
| Myocardial infarction |  | The median follow-up was 31.6 months | 
| heart failure readmission | readmission to any hospital due to diagnosed heart failure | The median follow-up was 31.6 months | 
| Stroke | defined using the World Health Organization criteria | The median follow-up was 31.6 months |
Behavioral Signs of Consciousness Recovery in Patients With Disorders of Consciousness (DOCSIGNS)

Study Overview
=================
Brief Summary
-----------------
Precise description of behavioral signs denoting transition from unresponsive wakefulness syndrome/vegetative state (UWS/VS) to minimally conscious state (MCS) or emergence from MCS after severe brain injury is crucial for prognostic purposes. A few studies have attempted this goal but involved either non-standardized instruments, limited temporal accuracy or samples, or focused on (sub)acute patients. The objective of this study is to describe the behavioral signs that led to a change of diagnosis, as well as the factors influencing this transition, in a large sample of patients with chronic disorders of consciousness after severe brain injury.

Official Title
-----------------
Investigation of the Behavioral Signs of Consciousness Recovery in Patients With Disorders of Consciousness (DOCSIGNS)

Conditions
-----------------
Consciousness Disorder, Brain Injuries

Intervention / Treatment
-----------------
* Behavioral: Rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: documented medical diagnosis of CRS-R-based diagnosis of UWS or MCS at admission to the neurorehabilitation program Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Disorders of consciousness<br>Patients diagnosed as either in a Vegetative State or in a Minimally Conscious State | Behavioral: Rehabilitation<br>* Multidisciplinary rehabilitation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline score in the Coma Recovery Scale-Revised until study completion | The Coma Recovery Scale-Revised consists of 29 hierarchically organised items divided into 6 subscales addressing auditory, visual, motor, oromotor, communication, and arousal processes. | From inclusion in the study until discharge or death, assessed up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline score in the Functional Independence Measure until study completion | The Functional Independence Measure is an 18-item measurement tool that explores an individual's physical, psychological and social function | From inclusion in the study until discharge or death, assessed up to 24 months | 
| Change from baseline score in the Disability Rating Scale until study completion | The Disability Rating Scale is an 8-item measure that assesses disability of individuals with moderate to severe traumatic brain injury at a wide range of functional levels from coma through community living | rom inclusion in the study until discharge or death, assessed up to 24 months |
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

Study Overview
=================
Brief Summary
-----------------
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)

Detailed Description
-----------------
An open-label, long-term study to evaluate the safety of inhaled nitric oxide (iNO) in subjects with pulmonary arterial hypertension (PAH) who participated in IK-7001-PAH-201 and PULSE-PAH-004 to provide these patients with continued access to chronic iNO until the time of approval or development of iNO in PAH is discontinued.

Official Title
-----------------
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for PAH for Subjects in the PULSE-PAH-006 and PULSE-PAH-004 Studies Who Continue to Need iNO Therapy

Conditions
-----------------
Pulmonary Arterial Hypertension

Intervention / Treatment
-----------------
* Drug: Inhaled Nitric Oxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed Informed Consent Form prior to the initiation of any study mandated procedures or assessments. PAH subjects who have completed all EOS assessments in IK-7001-PAH-201 and PULSE-PAH-004 and have continued drug/device usage. Subjects are willing and considered in the judgement of the Investigator able to use the INOpulse device continuously for up to 24 hours per day. All female subjects must be willing to continue to take adequate precaution to avoid pregnancy. Subjects in need for continued treatment with iNO in the opinion of the treating physician and agreement from Sponsor. Exclusion Criteria: Subjects who require treatment with riociguat Subjects who early discontinued drug/device usage due to withdrawal of consent or an AE requiring termination from treatment in IK-7001-PAH-201
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Open Label Extension
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inhaled Nitric Oxide (iNO)<br>Pulsed iNO 75 mcg/kg IBW/hour | Drug: Inhaled Nitric Oxide<br> <br> * Other names: iNO;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Serious Adverse Events | Incidence of Serious Adverse Events from baseline to end of study | Through Study Completion, anticipated 3 years | 
| Incidence of INOpulse device malfunction and/or device failure leading to an AE | Incidence of INOpulse device malfunction and/or device failure leading to an AE from baseline to end of study | Through Study Completion, anticipated 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PAH, Pulmonary Arterial Hypertension, Inhaled Nitric Oxide, iNO
A Wearable System to Monitor Tai Chi Practice

Study Overview
=================
Brief Summary
-----------------
The goal of this research study is to show that features derived from data gathered using SHIMMER wearable sensor platform can capture adherence and proficiency in the performance of exercises that are part of Tai Chi interventions.

Official Title
-----------------
A Wearable System to Monitor Tai Chi Practice

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Young style Tai Chi practitioners Exclusion Criteria: Any movement impairment that will impede Tai Chi movements performance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tai Chi<br>Healthy Tai Chi practitioners | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biomarkers of adherence and proficiency | Data gathered using SHIMMER devices will be segmented to derive signal features. These features will be then used to feed a pattern recognition algorithm the output of which indicates whether a specific Tai Chi movement of interest has been performed. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tai Chi, Wearable sensors, Movement
Prognosis Scoring System for Acute-on-Chronic Liver Failure

Study Overview
=================
Brief Summary
-----------------
This research is to establish a simple and practical system to predict the prognosis of sever hepatitis B.Seven factors (level of serum total bilirubin, prothrombin time, severity of hepatic encephalopathy, hepatorenal syndrome,ascites ,infection and size of liver) which were easier to evaluate and more influential， were included to establish a prognosis scoring system．The scorings of a new score system and MELD were graded at the same time in the patients with sever hepatitis B. And then the distribution figures of survival rates and mortality rates were done according to the scores from low to high. The features of distribution figures of two score system in survival rates and mortality rates and significances of clinical application in certain score were interpreted.

Conditions
-----------------
Liver Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: serum hepatitis B surface antigen(HBsAg) positive for at least 6 months; All patients had a poor general condition, manifested as general malaise, fatigue, jaundice and so on; serum T-Bil of 171 mmol/L or more; or serum T-Bil rises 17.1 mmol/L or more per day; Exclusion Criteria: superinfection or co-infection with hepatitis A, C, D, E, cytomegalovirus and HIV, or Epstein-Barr virus; other liver diseases such as alcoholic liver disease, drug-induced hepatitis, Wilson disease and autoimmune hepatitis; ascites or gastrointestinal bleeding or peptic ulcer or esophageal varix by electronic gastroscope examination; decompensated liver cirrhosis; severe bacterial or fungal infections; a history of diabetes or cardiac disease or hypertension or nephrosis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival rate |  | twelve weeks |
D-serine for Posttraumatic Stress Disorder Treatment

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance& depressive symptomatology that may be mediated by NMDA receptor function deficits. Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine ( 2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.

Official Title
-----------------
D-serine for Posttraumatic Stress Disorder Treatment

Conditions
-----------------
Posttraumatic Stress Disorder

Intervention / Treatment
-----------------
* Drug: D-serine ( 2g /day)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Chronic PTSD (DSM-IV diagnosis) Exclusion Criteria: Other psychiatric diagnosis Substance abuse Unstable medical condition

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Adjuvant 6 weeks treatment with placebo ( 2g /day) | Drug: D-serine ( 2g /day)<br>* Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine  2g /day), in the second arm adjuvant treatment with placebo ( 2g /day)<br>|
| Experimental: 2<br>Adjuvant 6 weeks treatment with D-serine ( 2g /day) | Drug: D-serine ( 2g /day)<br>* Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine  2g /day), in the second arm adjuvant treatment with placebo ( 2g /day)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAPS scores |  | 6 week treatment |